Drug DevelopmentHealth Canada has approved Edesa Biotech to conduct a Phase 2 trial of EB06 in moderate to severe nonsegmental vitiligo patients.
Financial PerformanceEdesa’s balance sheet is robustly positioned for the manufacturing of clinical-grade supplies of EB06, supported by $15M in gross proceeds from a recent private placement.
Market OpportunityThe prioritization of EB06, a monoclonal antibody candidate for the treatment of vitiligo, represents a significant market opportunity due to the large number of affected individuals in the U.S.